Clinical trials: Hemostatic Agents
B-cell Non Hodgkin Lymphoma
A Study of ARC-02 in B-cell NHL
This study is to assess safety, tolerability, pharmacokinetics (PK), pharmacodynamic (PD), and preliminary efficacy of ARC-02.
- Trial name
- ABLATE-101 (NCT07691606)
- Testing
- ARC-02, Rituximab
- Where
- 28 sites in United States, Australia and 4 more
- Volunteers
- 140 people
- Sponsor
- Taiho Oncology, Inc.
Multiple Myeloma
Diagnostic Imaging of Myeloma Bone Lesions
The purpose of this study is to compare the current standard whole-body x-ray with the advanced imaging techniques FDG-PET-CT, NaF-PET-CT and whole-body MRI in the detection of myeloma bone lesions.
- Trial name
- RAMP (NCT03147326)
- Testing
- FDG-PET-CT, NaF-PET-CT, Whole-body MRI
- Where
- Denmark
- Volunteers
- 14 people
- Sponsor
- Herlev Hospital
Graft Versus Host Disease, Leukemia
Donor White Blood Cell Infusions and Interleukin-2 in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Relapsed Advanced Lymphoid Cancer
RATIONALE: Drugs used in chemotherapy, such as melphalan, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00248430
- Testing
- aldesleukin, therapeutic allogeneic lymphocytes, melphalan
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Fred Hutchinson Cancer Center
Multiple Myeloma
Phase 1 Pharmacokinetic Study of Oral Ixazomib Plus Lenalidomide and Dexamethasone in Adult Asian Participants With Relapsed and/or Refractory Multiple Myeloma
The purpose of this Phase 1 study is to characterize the pharmacokinetic (PK) and tolerability of oral ixazomib (MLN9708) when administered in combination with lenalidomide and dexamethasone in adult Asian participants with…
- Trial name
- NCT01645930
- Testing
- Ixazomib, Lenalidomide, Dexamethasone
- Where
- 5 sites in Hong Kong, Singapore and 1 more
- Volunteers
- 43 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Multiple Myeloma
Induction Therapy for Multiple Myeloma With Carfilzomib, Lenalidomide,Dexamethasone,Panobinostat
The purpose of this study for Phase l is to determine the maximum tolerated dose of panobinostat given in combination with carfilzomib, lenalidomide, and dexamethasone in 28-day cycles as induction (initial) therapy to…
- Trial name
- NCT02802163
- Testing
- Panobinostat, Carfilzomib, Lenalidomide
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Benign Ovarian Cyst
Comparison of Hemostatic Agent to Suture in Terms of Hemostatic Function and Preservation of Ovarian Function
This study aims to evaluate the efficacy of preservation of ovarian function, hemostasis, and safety of a hemostatic agent versus suturing during laparoscopic ovarian cystectomy for ovarian endometriosis.
- Trial name
- PRAHA-2 (NCT04643106)
- Testing
- Hemostatic agent (EVICEL®) application during laparoscopic ovarian cystectomy, suturing with barbed sutures during laparoscopic ovarian cystectomy
- Where
- 2 sites in South Korea
- Volunteers
- 90 people
- Sponsor
- Seoul National University Hospital
Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma
Celecoxib in Preventing Multiple Myeloma in Patients With Monoclonal Gammopathy or Smoldering Myeloma
This randomized phase II trial studies how well celecoxib works in preventing multiple myeloma in patients with monoclonal gammopathy or smoldering myeloma.
- Conditions
- Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Smoldering Multiple Myeloma
- Trial name
- NCT00099047
- Testing
- celecoxib, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- National Cancer Institute (NCI)
Bleeding Disorder
Early Genomic Testing for Inherited Bleeding Disorders
The investigators aim to test the introduction of genomic testing early in the diagnostic pathway for inherited bleeding disorders in patients who have not received a diagnosis after first-line testing.
- Trial name
- GT4BD (NCT06736158)
- Testing
- Genetic testing for inherited bleeding disorders
- Where
- 3 sites in Canada
- Volunteers
- 212 people
- Sponsor
- Queen's University
Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma
This phase I/II trial tests the safety, side effects, best dose, and effectiveness of iberdomide in combination with belantamab mafodotin and dexamethasone in treating patients with multiple myeloma (MM) that has come back after…
- Trial name
- NCT06232044
- Testing
- Iberdomide, Belantamab Mafodotin, Dexamethasone
- Where
- 43 sites in United States
- Volunteers
- 88 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
SMAC Mimetic LCL161 Alone or With Cyclophosphamide in Treating Patients With Relapsed or Refractory Multiple Myeloma
This phase II trial studies how well second mitochondrial-derived activator of caspases (SMAC) mimetic LCL161 alone or with cyclophosphamide works in treating patients with multiple myeloma that has returned or does not respond…
- Trial name
- NCT01955434
- Testing
- Cyclophosphamide, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 3 sites in United States
- Volunteers
- 25 people
- Sponsor
- Mayo Clinic
Multiple Myeloma
Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant
The purpose of this study is to evaluate whether elranatamab monotherapy can provide clinical benefit compared to lenalidomide monotherapy (control) in participants with newly diagnosed multiple myeloma after undergoing…
- Trial name
- MagnetisMM-7 (NCT05317416)
- Testing
- Elranatamab, Lenalidomide
- Where
- 209 sites in United States, Australia and 25 more
- Volunteers
- 854 people
- Sponsor
- Pfizer
Henoch-Schönlein Purpura
Clinical Study on Strategy for Refractory Henoch-Schönlein Purpura
IgA vasculitis is relatively common in children,especially in Asian countries. Abdominal manifestation could be severe, including bleeding, pancreatitis,appendicitis and intestinal intussusception.
- Trial name
- NCT03647852
- Testing
- Methylprednisolone, IVIG, other basic supportive treatment
- Where
- 3 sites in China
- Volunteers
- 150 people
- Sponsor
- Children's Hospital of Fudan University
Multiple Myeloma
Expanded Natural Killer (NK) Cells for Multiple Myeloma Study
High-dose chemotherapy with melphalan and autologous hematopoietic stem cell transplantation (HSCT) is considered standard treatment for patients with multiple myeloma.
- Trial name
- NCT01040026
- Testing
- Treatment with in vitro expanded haploidentical NK cells
- Where
- Switzerland
- Volunteers
- 10 people
- Sponsor
- University Hospital, Basel, Switzerland
Multiple Myeloma
Hemostatic Effects of VELCADE®* Treatment in Multiple Myeloma Patients
To evaluate the effect of VELCADE on platelet aggregation at baseline, 24 hours and 48 hours after infusion in patients with multiple myeloma
- Trial name
- NCT01720043
- Testing
- Velcade
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Utah
Multiple Myeloma
Study of BTK Inhibitor, Ibrutinib in Combination With Carfilzomib in Subjects With Relapsed and Refractory Multiple Myeloma
A MULTICENTER PHASE 1/2B STUDY OF THE BRUTON'S TYROSINE KINASE INHIBITOR, IBRUTINIB (PCI-32765), IN COMBINATION WITH CARFILZOMIB (KYPROLIS™) IN SUBJECTS WITH RELAPSED OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA
- Trial name
- NCT01962792
- Testing
- Ibrutinib, Carfilzomib, Dexamethasone
- Where
- 17 sites in United States, Canada
- Volunteers
- 84 people
- Sponsor
- Pharmacyclics LLC.
Relapsed or Refractory Multiple Myeloma
A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to compare the safety and efficacy of QLS32015 with Pd/Sd for the treatment of relapsed or refractory multiple myeloma.
- Trial name
- NCT07138209
- Testing
- QLS32015, Pomalidomide, Selinexor
- Where
- China
- Volunteers
- 228 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Waldenstrom's Macroglobulinemia
Combination Bortezomib and Rituximab in Patients With Waldenstrom's Macroglobulinemia (WM)
In this study, we are trying to find out if the combination of these two drugs is effective in treating Waldenstrom's macroglobulinemia (WM).
- Trial name
- NCT00422799
- Testing
- Bortezomib, Rituximab
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Dana-Farber Cancer Institute
Hip Fractures, Anticoagulants and Bleeding Disorders
Caudal Block & Hip Fracture Surgery in Anticoagulated Patient
Hip fractures are common in elderly patients, and require surgery. Many elderly patients take anticoagulants for vasculopathy treatment.
- Trial name
- NCT05946863
- Where
- Canada
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Salem Anaesthesia Pain Clinic
Multiple Myeloma
Genomic-Based Diagnosis, Classification and Targeted Treatment of Multiple Myeloma
Multiple myeloma is an incurable bone marrow cancer characterized by an abnormal expansion of plasma cells that secretes monoclonal immunoglobulin.
- Trial name
- NCT01619358
- Where
- Singapore
- Volunteers
- 150 people
- Sponsor
- National University Hospital, Singapore
Multiple Myeloma Refractory, Relapsed Multiple Myeloma
Immunoglobulins in Multiple Myeloma Patients Receiving a BCMA-Directed T Cell Engager
Bispecific antibody therapies targeting BCMA (B-cell maturation antigen) represent a novel therapeutic approach for patients with multiple myeloma.
- Trial name
- CHUQUL_HO001 (NCT07094048)
- Testing
- Target trough IgG level of 8-10 g/L, Target trough IgG level 4-6 g/L, No history of recurrent or severe infections and total IgG level higher or equal at 4 g/L
- Where
- 2 sites in Canada
- Volunteers
- 80 people
- Sponsor
- CHU de Quebec-Universite Laval
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.